Redeye provides its comments on Optomed’s Q2’22 report.
Profit before tax came in 8% above ABGSC Strong quarter in the insurance business Guidance for ’2...
Dovre revised its guidance up earlier than we expected.
Suominen reports Q2 results on Tue, Aug 9. We continue to expect q/q improvement over the weak Q1 re...
CapMan's net sales in Q2 amounted to EUR 17.7m, slightly above our estimates and in line with consen...
Redeye comments on EG7 ahead of its Q2-results (due 23 August) where we expect stable performance dr...
Q1 was characterised by unfavourable weather conditions, cautious customers and a high level of sick...
Q2: weaker profitability on lower GM and higher opex Continues to ramp up e-com investments Double...
Med Q2-rapporten presenterad står det klart att Maven Wireless AB (”Maven” eller ”Bolaget”) avslutar...
Detection Technology’s Q2 net sales came down less than we expected.
Redeye updates its estimates prior to the Q2 report, following the selling of two Infrahubs projects...
Redeye is updating its estimates and valuation of Invisio after the Q2 report, which came in weaker ...
Redeye gives a short comment on the ACD856 Phase I “MAD” data presented at the AAIC conference and r...
Infreas båda affärsområden visar goda resultat under första halvåret och fortsätter denna utveckling...
Redeye uppdaterar estimat och värdering på Invisio efter Q2-rapporten som kom in svagare än väntat p...
NoHo upgraded its guidance on 22 June due to strong demand in the spring and early summer, as well a...
Atvexa’s Q3 report showed growth, margin expansion and strong FCF generation.
Redeye is encouraged to see another quarter in which IRRAS continues to lay the building blocks for ...
We expect Netcompany to have enjoyed solid order intake in Q2 and so far in Q3, notably within the p...
The long-awaited FDA decision announced on 30 July Management looks to have the test available by ...
